Nesina (nes-SEE-na, alogliptin) will compete for your prescription in a crowded market of gliptins for type 2 diabetes

August 2013

Nesina (nes-SEE-na, alogliptin) will compete for your prescription in a crowded market of gliptins for type 2 diabetes.

This new DPP-4 inhibitor is a "me too"...similar to Januvia (sitagliptin), Onglyza (saxagliptin), and Tradjenta (linagliptin).

Continue to recommend lifestyle changes and metformin first.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

COPD new ideas about managing COPD patients
Infectious Diseases NOT using azithromycin or other macrolides for most acute respiratory infections
Statins Your statin patients will ask if they should AVOID exercise
Antithrombotics more debate about using antithrombotics to prevent strokes in elderly patients with atrial fibrillation
Ophthalmology a new version of PreserVision AREDS 2 for age-related macular degeneration (AMD)
Contraceptives Questions will come up now that levonorgestrel emergency contraceptives will be available OTC without restrictions
Diabetes Nesina (nes-SEE-na, alogliptin) will compete for your prescription in a crowded market of gliptins for type 2 diabetes
Dermatology questions about treating rashes caused by poison ivy, poison oak, or poison sumac
Acne more opportunities to help kids and teens with acne
Psychiatry using varenicline (Chantix) for ALCOHOL abuse and dependence
Patient Privacy/HIPAA changes in HIPAA privacy and security rules, which need to be implemented by September 23